Acumen Pharmaceuticals, Inc. Lease, Cost
Acumen Pharmaceuticals, Inc. (ABOS) reported Lease, Cost of $56.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2024-08-13
- Acumen Pharmaceuticals, Inc. lease, cost for the quarter ending 2024-06-30 was $56.00K, a 51.35% increase year-over-year.
- Acumen Pharmaceuticals, Inc. lease, cost for the quarter ending 2024-03-31 was $62.00K, a 63.16% increase year-over-year.
- Acumen Pharmaceuticals, Inc. lease, cost for the quarter ending 2023-06-30 was $37.00K.
- Acumen Pharmaceuticals, Inc. lease, cost for the quarter ending 2023-03-31 was $38.00K.
- Acumen Pharmaceuticals, Inc. lease, cost for fiscal 2023 was $160.00K, a 29.03% increase from fiscal 2022.
- Acumen Pharmaceuticals, Inc. lease, cost for fiscal 2022 was $124.00K.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 12 month |
|---|---|---|---|
| 2024-06-30 | $56.00K 10-Q · filed 2024-08-13 | $118.00K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $62.00K 10-Q · filed 2024-05-14 | ||
| 2023-12-31 | $160.00K 10-K · filed 2024-03-26 | ||
| 2023-06-30 | $37.00K 10-Q · filed 2024-08-13 | $75.00K 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $38.00K 10-Q · filed 2024-05-14 | ||
| 2022-12-31 | $124.00K 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |